In order to succeed, we must capitalize on the expertise of individuals and groups that have been quietly, diligently, and independently studying such diseases. They must share with those at the front lines of the battle information about diseases’ natural history, modes of transmission, and risk factors, as well as preclinical data on – and clinical responses to – experimental treatments.